Suppr超能文献

一种与HER2阳性乳腺癌新辅助化疗反应、预后及淋巴细胞浸润相关的基质免疫模块与激素通路呈负相关。

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.

作者信息

Hamy Anne-Sophie, Bonsang-Kitzis Hélène, Lae Marick, Moarii Matahi, Sadacca Benjamin, Pinheiro Alice, Galliot Marion, Abecassis Judith, Laurent Cecile, Reyal Fabien

机构信息

Institut Curie, PSL Research University, Translational Research Department, INSERM, U932 Immunity and Cancer, Residual Tumor & Response to Treatment Laboratory (RT2Lab), Paris, France.

Department of Surgery, Institut Curie, Paris, France.

出版信息

PLoS One. 2016 Dec 22;11(12):e0167397. doi: 10.1371/journal.pone.0167397. eCollection 2016.

Abstract

INTRODUCTION

HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions.

METHODS

We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset).

RESULTS

We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the "Immunity" metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28-11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36-0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs).

CONCLUSION

The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.

摘要

引言

人表皮生长因子受体2(HER2)阳性乳腺癌(BC)是一组侵袭性乳腺癌的异质性群体,自引入针对HER2的治疗方法以来,其预后有了很大改善。然而,这些肿瘤可能对治疗表现出内在或获得性耐药,因此需要HER2阳性肿瘤的分类器来改善预后预测并开发新的治疗干预措施。

方法

我们分析了来自21个公开可用数据集的2893份原发性人类乳腺癌样本,并在448例HER2阳性BC的训练集上开发了一个六元基因特征。然后,我们使用外部公开数据集来评估这些元基因预测化疗反应(伊格纳蒂亚迪斯数据集)和预后(METABRIC数据集)的能力。

结果

我们鉴定出一个包含在不同基因本体中富集的元基因的六元基因特征(138个基因)。基因簇命名如下:免疫、肿瘤抑制因子/增殖、干扰素、信号转导、激素/存活和基质簇。在所有数据集中,免疫元基因在雌激素受体(ER)阳性肿瘤中的表达强度低于ER阴性肿瘤,并且与激素/存活元基因呈负相关。在该特征中,多变量分析表明,与弱表达相比,“免疫”元基因的强表达与新辅助化疗(NAC)后更高的病理完全缓解(pCR)率相关(比值比[OR]=3.71[1.28 - 11.91],p = 0.019),并且与HER2阳性/ER阴性乳腺癌的更好预后相关(风险比[HR]=0.58[0.36 - 0.94],p = 0.026)。免疫元基因表达与肿瘤浸润淋巴细胞(TILs)的存在相关。

结论

在HER2阳性BC中鉴定出一个预测性和预后性免疫模块,证实了对该特定亚型进行免疫检查点调节剂和疫苗的临床检测的必要性。免疫与激素途径之间的负相关开启了研究前景,值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd3f/5178998/a3a5bd6fa90a/pone.0167397.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验